Mendra

Based in the US, Mendra is focused on developing innovative therapeutics for rare and ultra-rare diseases, utilizing advanced technologies to enhance clinical development and bring necessary treatments to market. Mendra Therapeutics operates in the rare disease sector, focusing on therapeutic development. Founded in 2025 in San Francisco, US, the company has undertaken its first investment deal in January 2026, securing USD 82 mn in Series A funding led by OrbiMed Advisors, 8VC, and 5AM Ventures, with contributions from Lux Capital and Wing. The total amount raised to date is USD 82 mn.

Mendra Therapeutics specializes in developing innovative therapeutics for rare and ultra-rare diseases, leveraging artificial intelligence to expedite clinical development and commercialization processes. The company's core offerings include advanced biopharmaceutical products designed to address significant unmet medical needs. Mendra collaborates with academic researchers, biotech firms, and patient foundations to facilitate funding, licensing, and commercialization of these therapies, creating pathways for scientists to bring discoveries to market. Its products primarily serve patients diagnosed with rare diseases and their families, as well as healthcare providers involved in treatment.

Mendra's initiatives target markets across North America, Europe, and select regions in Asia, ensuring a global reach for its innovations. Mendra Therapeutics generates revenue through strategic partnerships and collaborations with research and development-stage biotech companies, focusing on high-potential therapies. The firm's transaction structure typically involves licensing agreements and co-development partnerships, allowing for shared risk in advancing therapeutics to market. The company may also engage in direct-to-consumer sales for select products, providing access to life-saving treatments.

While specific pricing plans and revenue figures for individual products are proprietary, Mendra's revenue model reflects its commitment to delivering impactful therapies within the rare disease sector. Mendra aims to leverage the recent funding of USD 82 mn from its Series A round, concluded in January 2026, to acquire and develop rare disease assets, establish lean commercial infrastructure, and apply AI technologies to enhance patient identification, clinical trial enrollment, and global market access. The strategy includes upcoming product launches designed to cater to patients with high unmet needs, alongside expansion into additional geographic regions, including strategic markets in Europe and Asia, expected to occur within the next two years.